78 articles - From Friday Jun 10 2022 to Friday Jun 17 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Ann Oncol |
| CA Cancer J Clin |
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. The literature review, consensus statements, and algorithms presented in this report can serve as a framework guiding treatment decisions for patients. CA Cancer J Clin. 2022; 72:000-000. |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Am J Hematol |
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. FLT3-ITD mutation was associated with inferior survival in intermediate-1 (p=0.004) and TP53 in intermediate-2 (p=0.06) and high (p=0.02) risk disease; the latter was fully accounted for by the close association between TP53 mutation and complex/monosomal karyotype while the observations regarding FLT3-ITD were not affected by treatment with midostaurin. AHSCT had a favorable impact on survival, most apparent in intermediate-1 (p<0.001), intermediate-2 (p=0.03), and high (p=0.01) risk disease. The proposed 3-factor survival model offers a novel prototype that is amenable to further enhancement by molecular information and was validated in an external cohort of 1,032 intensively-treated AML patients. |
HLA-haploidentical transplantation for relapsed/refractory AML: better LFS with BM than with PBSC in patients = 55 years of age. In contrast, in patients =55 |
| Ann Oncol |
Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas. Bendamustine for lymphodepletion before tisagenlecleucel has efficacy similar to fludarabine/cyclophosphamide with reduced toxicities, including CRS, neurotoxicity. infectious and hematological toxicities, as well as reduced hospital utilization. |
Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study. Pembrolizumab demonstrated clinically meaningful and durable benefit, with high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting. |
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase 3 trial. Pimitespib significantly improved PFS and crossover-adjusted OS compared with placebo and had an acceptable safety profile in patients with advanced GIST refractory to standard TKIs. |
Whole genome and transcriptome analysis enhances precision cancer treatment options. Integrating RNA expression and genome data illuminated treatment options that resulted in 46% of treated patients experiencing positive clinical benefit, supporting the use of comprehensive WGTA profiling in clinical cancer care. Clinical trial number NCT02155621. |
| Blood |
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Expression of this EVI1 splice variant enhanced the self-renewal of hematopoietic stem cells and introduction of mutant SF3B1 in mice bearing the humanized inv(3)(q21q26) allele resulted in generation of this novel EVI1 isoform in mice and hastened leukemogenesis in vivo. The mutant SF3B1 spliceosome depends upon an exonic splicing enhancer within EVI1 exon 13 to promote usage of a cryptic branch point and aberrant 3' splice site within intron 12 resulting in the generation of this isoform. These data provide a mechanistic basis for the frequent co-occurrence of SF3B1 mutations as well as new insights into the pathogenesis of myeloid leukemias harboring inv(3)/t(3; 3). |
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. The ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 compared to 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95%CI: 5.6-46.9) and 8.9 (95%CI: 4.3-18.3). Compared to available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints. This study suggests axi-cel may address an important unmet need for r/r FL patients. |
Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma. However, its cost-effectiveness is highly dependent on its long-term outcomes and CAR-T cost. Routine usage of pola-R-CHP would add significantly to healthcare expenditures. Price reductions or identification of subgroups that have maximal benefit would improve cost-effectiveness. |
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. As we found loss of BAX in Richter's syndrome patients after venetoclax failure, we defined BAX-mediated apoptosis to be critical for drug resistance but not for disease progression of CLL into aggressive DLBCL in vivo. A compound screen revealed TRAIL-mediated apoptosis as a target to overcome BAX deficiency. Furthermore, antibody or CAR T cells eliminated venetoclax resistant lymphoma cells, paving a clinically applicable way to overcome venetoclax resistance. |
KIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target. To conclude, KIR3DL2 expression is associated with acute-type ATL. Transcription of KIR3DL2 might be triggered by HTLV-1 infection and is correlated with hypomethylation of the promoter. The benefit of targeting KIR3DL2 with lacutamab is being further explored in a randomized phase 2 study in peripheral T-cell lymphoma, including ATL (NCT04984837). |
Quercetin Ameliorates XIAP Deficiency Associated Hyperinflammation. In experiments using human cells, quercetin greatly reduced IL-1ß secretion by monocytes following TNF-a stimulation (p<0.05). Our data suggest that quercetin may be an effective natural therapeutic for the prevention of XIAP deficiency-associated hyperinflammation. Clinical trials, including careful pharmacokinetic and pharmacodynamic studies to ensure that effective levels of quercetin can be obtained, are warranted. |
Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy. Both the switch to alternative pro-survival factors and NF-kB activation largely dissipate following venetoclax discontinuation. Our studies reveal the extent of plasticity of CLL cells in their ability to evade venetoclax-induced apoptosis. Importantly, these findings pinpoint new approaches to circumvent venetoclax resistance and provide a specific biological justification for the strategy of venetoclax discontinuation once maximal response is achieved rather than maintaining long-term selective pressure with the drug. |
The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. In contrast, argatroban showed no effect on procoagulant platelets and aggregation but significantly inhibited VITT-mediated thrombus formation. Taken together, our data indicate that negatively charged anticoagulants can disrupt VITT-Ab/PF4 interactions, which might serve as an approach to reduce Ab-mediated complications in VITT. Our results should be confirmed, however, in a clinical setting before a recommendation regarding the selection of anticoagulants in VITT patients could be made. |
Unique characteristics of lung resident neutrophils are maintained by PGE2/PKA/Tgm2-mediated signaling. Neutrophils from Tgm2-/- mice release high levels of inflammatory cytokines in response to LPS. Lung damage is significantly exacerbated in Tgm2-/- mice in an LPS-induced acute respiratory distress syndrome model. Collectively, we demonstrate that prostaglandin E2 is a key factor for the generation of LNs with unique immune suppressive characteristics, acting through protein kinase A and Tgm2, and LNs play essential roles in the protection of the lungs against pathogenic inflammation. |
| Blood Adv |
CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy. I115F mice was in platelet clearance and in the levels of platelet cytosolic basal Ca2+. Both were restored upon treatment of animals with CIC-39Na. This finding paves the way to a pharmacological treatment strategy for thrombocytopenia in tubular aggregate myopathy patients. |
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study. Both calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP. |
Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide coated nanoparticles. We found that the CpG/PTT groups had significant reduction in growth in both treated (primary) and untreated (secondary) tumors suggesting an improved abscopal response, with a concomitant increase in CD8/CD4 ratio and cytotoxic T cell/regulatory T cell ratio in both the primary and secondary tumor compared with CpG/RT. Dendritic cells in the primary and secondary draining lymph nodes had increased maturation markers in the CpG/PTT group, and the effector memory T cells (both CD4 and CD8) in the secondary tumor and the spleen were increased, suggesting a systemic vaccination effect. These data suggest that in a lymphoma model, PTT using a CpG nanoparticle platform resulted in enhanced in situ vaccination and abscopal response compared with RT. |
Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines. Silvestrol and Dinaciclib generally showed outstanding activities and the newly derived cell lines tended to be most responsive. The BL cell line Jijoye showed a completely different pattern of response. A panel of well characterized D/TH lymphoma lines would be very helpful in preclinical studies of targeted agents. |
Genomic characterization of lymphomas in patients with inborn errors of immunity. The latter, BRWD3, is furthermore preferentially mutated in tumors of a subgroup of activated phosphoinositide 3-kinase delta (PI3Kd) syndrome patients. We also identified five genomic mutational signatures, including two DNA repair deficiency-related signatures, in IEI-associated lymphomas and a strikingly high number of inter- and intrachromosomal structural variants in the tumor genome of a Bloom syndrome patient. In summary, our comprehensive genomic characterization of lymphomas derived from patients with rare genetic disorders expands our understanding of lymphomagenesis and provides new insights for targeted therapy. |
Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study. Hematotoxicity after chimeric antigen receptor (CAR)-T cell therapy is associated with infection and death but management remains unclear. We report results of 31 patients receiving hematopoietic stem cell boost (HSCB; 30 autologous, 1 allogeneic) for either sustained severe neutropenia of grade 4 ( 38 days prior to HSCB (44%; p=0.029). In conclusion, early or prophylactic HSCB showed quick response and improved outcomes for sustained moderate to severe neutropenia after CAR-T. |
In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently over-expressing cxcr4. In vivo transduction with a HDAd5/3+GFP/cxcr4 vector at a low dose of 0.4x1012vp/kg resulted in up to 7% of GFP-positive CD34+/CD45RA-/CD90+ cells in the bone marrow. This transduction rate is a solid basis for in vivo base or prime editing in combination with natural or drug-induced expansion of edited HSCs. Furthermore, our study provides new insights into HSC biology and trafficking after mobilization in non-human primates. |
Longitudinal Study of Glomerular Hyperfiltration in Adults with Sickle Cell Anemia: A Multicenter Pooled Analysis. Using CKD-EPI-2009, this decline was associated with male sex (HR: 2.20, 95%CI: 1.26, 3.87; p=0.006), systolic blood pressure (SBP) (HR: 1.02, 95%CI: 1.01, 1.04; p=0.01) and hydroxyurea use (HR: 1.74, 95%CI: 1.002, 3.03; p=0.05). Using CKD-EPI-2021, decline of eGFR to normal was only associated with male sex (HR: 3.39, 95% CI: 2.01, 5.69; p<0.0001). Decline to normal eGFR range from hyperfiltration occurs earlier in males, those on hydroxyurea and with higher SBP. |
Non-canonical Sonic Hedgehog signaling amplifies platelet reactivity and thrombogenicity. Remarkably, agonist-induced thrombogenic responses in platelets, which include platelet aggregation, granule secretion and spreading on immobilized fibrinogen, were significantly attenuated by inhibition of Hedgehog signaling, thus implicating inputs from Shh in potentiation of agonist-mediated platelet activation. In consistence, inhibition of Shh pathway significantly impaired arterial thrombosis in mice. Taken together, above observations strongly support a feed-forward loop of platelet stimulation triggered locally by Shh, similar to ADP and thromboxane A2, that contributes significantly to stability of occlusive arterial thrombus and that can be investigated as potential therapeutic target in thrombotic disorders. |
Nurse-like cells sequester B cells in chronic lymphocytic leukemia disorganized lymph nodes via an alternative production of CCL21. Our results indicate NLCs as providers of an alternative source of CCL21, taking over the physiological task of follicular reticular cells (FRCs) whose network is deeply altered in CLL lymph nodes. Moreover, CCL21, by retaining malignant B cells, provide a protective environment for their niching and survival thus allowing immune tumor survey evasion and resistance to treatment. These findings argue for a specific targeting or re-education of NLCs as a new immunotherapy strategy for this still deadly disease. |
Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. In this context, we observed that harboring more than 3 mutated genes, ASXL1 mutations and a peripheral blood monocyte percentage above 20% significantly predicted shorter time of progression of OM-CMML into overt CMML. These variables were also detected as independent adverse prognostic factors for OS in OM-CMML. These data support the consideration of OM-CMML as the first evolutionary stage within the proliferative continuum of CMML. |
Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. Incidence of major bleeding events per 100 person-years in high- and non-high-risk patients, respectively, were 3.9 (95% confidence interval, 3.0-5.1) and 1.1 (0.8-1.4) using the newly derived CHAP model (creatinine, hemoglobin, age, and use of antiplatelet agent), 3.3 (2.6-4.1) and 1.0 (0.7-1.3) using modified ACCP, 5.3 (0.6-19.2) and 1.7 (1.4-2.0) using modified RIETE, 3.1 (2.3-3.9) and 1.1 (0.9-1.5) using modified VTE-BLEED, 5.2 (3.3-7.8) and 1.5 (1.2-1.8) using modified HAS-BLED, and 4.8 (1.3-12.4) and 1.7 (1.4-2.0) using modified OBRI scores. Modified versions of the ACCP, VTE-BLEED, and HAS-BLED scores help identify patients with unprovoked VTE who are at high risk of major bleeding and should be considered for discontinuation of anticoagulation after 3-6 months of initial treatment. The CHAP model may further improve estimation of bleeding risk by using continuous predictor variables, but external validation is required before its implementation in clinical practice. |
Risk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy. In a landmark analysis at one year, DM patients with lymphoma had decreased risks of insulin dependency compared to comparators. Time-varying IRRs showed a higher CVD risk for NHL patients with DM as compared to comparators in the first year after treatment. NHL patients treated with steroid-containing immunochemotherapy regimens have a clinically insignificant increased risk of DM in the first year following treatment, and patients with pre-existing DM have a temporary increased risk of insulin prescriptions and CVD. |
| Haematologica |
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. An Andersen-Gill regression model on OS revealed ELN favorable-risk (HR, 0.34; P=0.006) and trisomy 4 as sole abnormality (HR, 0.41 P=0.01) as favorable factors, whereas age with a difference of ten years (HR, 1.15, P=0.11), female gender (OR, 0.74; P=0.20) and allo-HCT (OR, 0.64; P=0.14) had no significant impact. In our cohort, patients with trisomy 4 as a sole abnormality had a high CR rate and favorable clinical outcome. Allo-HCT seems not to improve OS. |
Immune thrombocytopenia (ITP): diagnosis including secondary ITP, and selection of second line treatment During review of potential second-line treatment options, we also briefly touch upon novel treatments. Finally, there is a short section on refractory disease drawn from our extensive review in Blood in February 2020(1). The clinical nature of the discussions replete with figures and tables and with interspersion of pearls regarding efficacy and toxicity at different ages and genders, will serve the reader in management of "typical" adult patients who develop persistent and chronic ITP. |
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome. The median overall survival (OS) of 63 patients (43/63 only received chemotherapy after initial surgery) was 7.8 months. Multivariate analysis found a strong negative impact on outcome of MYC expression, TP53 mutation, STAT5B mutation and poor performance status while aberrant B-cell marker expression (20% of cases) correlated with better survival. In conclusion, MEITL is an aggressive disease with resistance to conventional therapy, predominantly characterized by driver gene alterations deregulating histone methylation and JAK/STAT signalling and encompasses genetic and morphologic variants associated with very high clinical risk. |
PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells. Response at M3 evaluated in 90 (57%) patients was prognostic for PFS with lower discrimination (HR=3.28 (95%CI: 1.5-7.0), p=0.003) but did not predict OS (HR = 0.61 (95%CI: 0.2-2.3) p=0.45). Patients with high baseline total metabolic tumor volume (TMTV) >80ml had worse PFS (HR=2.05 (95%CI: 1.2-3.5), p=0.009) and OS (HR=4.52 (95%CI: 2.5-8.1), p80ml, and DS-5 at M1 for OS. In conclusion, baseline TMTV and response at M1 strongly predicts outcomes of patients with R/R LBCL undergoing CAR T-cells. |
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. For prediction of CR and 2-year OS, AUROCs ranged between 0.77 - 0.86 and 0.63 and 0.74, respectively in our test set and 0.71 - 0.80 and 0.65 - 0.75 in the external validation cohort. We demonstrate the feasibility of ML for risk stratification in AML as a model disease for hematologic neoplasms using a scalable and reusable ML framework. Our study illustrates the clinical applicability of ML as a decision support system in hematology. |
| J Hematol Oncol |
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. The type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230. |
| Lancet Haematol |
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. Our study supports short treatment if patients are afebrile after 3 days of carbapenem treatment. However, because secondary analyses suggested that serious adverse events and all-cause mortality occurred more often in patients who are presistantly febrile the short treatment group, we recommend vigilance for non-susceptible pathogens and early resumption of empirical therapy in patients who are deteriorating. Funding The Netherlands Organisation for Health Research and Development and Fonds NutsOhra. |
| Leukemia |
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. However, the CalDDR-GEx10 score was not associated with clinical outcome in patients treated with standard chemotherapy alone (ADE, N |
CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL. Investigation of metabolism in vitro and in vivo supported these findings, revealing reduced aerobic glycolysis and increased basal respiration in CD147 knockdown. In conclusion, our findings indicate that CD147 is of vital importance for ALK+ ALCL to maintain the high energy demand of rapid cell proliferation, promoting lactate export, and tumor growth. Furthermore, CD147 has the potential to serve as a novel therapeutic target in ALK+ ALCL, and warrants further investigation. |
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Significant transcriptional alterations were identified in double-lesion mice, which were associated with activation of proinflammatory signals and repression of signals maintaining genome stability. Finally, KDM6B inhibitor reduced BM repopulating activity of double-lesion mice and tumor burden in mice transplanted with BM-HSPCs from CMML patients with TET2 mutations. These data indicate that TET2 deficiency and KDM6B overexpression cooperate in CMML pathogenesis of and that KDM6B could serve as a potential therapeutic target in this disease. |
Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma. The genetic profiles of ENTKCLs from Asian and Hispanic ethnic groups showed striking similarity, indicating shared pathogenetic mechanism and tumor evolution. Interestingly, we discovered a novel functional cooperation between activating STAT3 mutations and loss of the TSG, PRDM1, in promoting NK-cell growth and survival. This study provides a genetic roadmap for further analysis and facilitates investigation of actionable therapeutic opportunities in this aggressive lymphoma. |
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. This subtle difference led to measurable transcript-type dependent variation in estimates of residual disease which could be corrected by (i) taking the qPCR amplification efficiency into account, (ii) using alternative RT-qPCR approaches or (iii) droplet digital PCR (ddPCR), a technique which is relatively insensitive to differences in amplification kinetics. In CML patients, higher levels of BCR::ABL1/GUSB were identified at diagnosis for patients expressing e13a2 (n |
| Thromb Haemost |
Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study. Intracranial bleeding, ischemic stroke, and mortality risks were higher for patients with CVT than matched patients with VTE and the general population, particularly within 6 months after diagnosis. |
Comparison of risk of serious cardiovascular events after haemorrhagic versus ischaemic stroke: a population-based study. The risk of subsequent cardiovascular events is similar between patients with incident haemorrhagic or ischaemic stroke. Patients with previous haemorrhagic stroke should be regarded as a population at very-high risk of subsequent CVD. |
Immunity in Stroke: The Next Frontier. On one side, stroke induces a local neuroinflammatory response, in which the inflammatory activation of glial, endothelial and brain-invading cells contributes to lesion progression after stroke. On the other side, ischemic brain injury perturbs systemic immune homeostasis and results in long-lasting changes of systemic immunity. Here, we briefly summarize current concepts in local neuroinflammation and the systemic immune responses after stroke, and highlight two promising therapeutic strategies for poststroke inflammation. |
Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings. In patients with AF, stable CAD, and preserved renal function, rivaroxaban underdose was associated with similar rates of thrombotic events but a lower incidence of hemorrhagic events than the standard dose. Clinical trial registration |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Hematol |
Bispecific T-cell engagers for treatment of multiple myeloma. TCEs are also in development targeting the G protein-coupled receptor, class C group 5 member D (GPRC5D) and the Fc receptor homologue 5 (FcRH5). Main toxicities are cytokine release syndrome and cytopenias. Here we review the current development and future directions of TCEs in MM. |
| Blood |
| Blood Cancer J |
Resistance to targeted therapies: delving into FLT3 and IDH. Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance. |
| CA Cancer J Clin |
Examining the interrelationships between mindfulness-based interventions, depression, inflammation, and cancer survival. Therefore, it is conceivable that mindfulness programs can affect survival in this population. There are limited data on the long-term effects of mindfulness on depression and inflammatory markers in patients with cancer, and there are potential barriers to the implementation of mindfulness-based interventions as part of a comprehensive treatment plan. Therefore, it is necessary to further explore these questions through longitudinal studies to establish a survival correlation. |
| J Hematol Oncol |
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. We will also outline existing immunotherapeutic strategies, with a special focus on immune checkpoint inhibitors, chimeric antigen receptor therapy, and dendritic cell vaccines. Finally, we will summarize key discoveries in the field and discuss currently active clinical trials, including combination strategies, burgeoning technology like nucleic acid and nanoparticle therapy, and novel anticancer vaccines. This review aims to provide the most updated summary of the field of immunotherapy for GBM and offer both historical perspective and future directions to help inform clinical practice. |
| Leukemia |
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. In this review, we present a comprehensive overview of technologies used for ctDNA detection and genotyping in B-cell lymphoma, focusing on pre-analytical and technical requirements, the advantages and limitations of various approaches, and highlight recent advances around improving sensitivity and suppressing technical errors. We broadly review potential applications of ctDNA in clinical practice and for translational research by describing how ctDNA might enhance lymphoma subtype classification, treatment response assessment, outcome prediction, and monitoring of measurable residual disease. We finally discuss how ctDNA could be implemented in prospective clinical trials as a novel surrogate endpoint and be utilized as a decision-making tool to guide lymphoma treatment in the future. |
Letters to the editors and authors’ replies
| Am J Hematol |
all remaining publications eg case reports, images of the month, etc…
| Blood |
| Blood Adv |
| Haematologica |
| Lancet Haematol |
| Leukemia |